Provided by Tiger Fintech (Singapore) Pte. Ltd.

PTC Therapeutics

49.68
+0.12500.25%
Volume:140.75K
Turnover:6.98M
Market Cap:3.92B
PE:-10.51
High:50.07
Open:49.11
Low:48.09
Close:49.55
Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Washington Trust, Centessa Pharma, Kingstone

Reuters
·
15 Mar

BUZZ-PTC Therapeutics rises as J.P.Morgan raises PT on potential drug launches

Reuters
·
14 Mar

PTC Therapeutics Inc : JP Morgan Raises Target Price to $78 From $72

THOMSON REUTERS
·
14 Mar

Citi says SMid biotechs alternative to large caps as it starts coverage

Investing.com
·
13 Mar

BUZZ-Citi starts coverage on 'insulated' SMid biotechs amid healthcare policy uncertainty

Reuters
·
13 Mar

PTC Therapeutics Inc : Citigroup Raises Target Price to $50 From $46

THOMSON REUTERS
·
13 Mar

PTC Therapeutics Raised to Neutral From Underperform by B of A Securities

Dow Jones
·
11 Mar

PTC Therapeutics upgraded to Neutral from Underperform at BofA

TIPRANKS
·
11 Mar

PTC Therapeutics Coverage Assumed by Morgan Stanley at Overweight

Dow Jones
·
08 Mar

Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (DNLI), Disc Medicine (IRON) and PTC Therapeutics (PTCT)

TIPRANKS
·
07 Mar

Analysts Conflicted on These Healthcare Names: PTC Therapeutics (PTCT), 4D Molecular Therapeutics (FDMT) and Biohaven Ltd. (BHVN)

TIPRANKS
·
05 Mar

Kiniksa Pharmaceuticals (KNSA) Soars 5.8%: Is Further Upside Left in the Stock?

Zacks
·
04 Mar

We Might See A Profit From PTC Therapeutics, Inc. (NASDAQ:PTCT) Soon

Simply Wall St.
·
01 Mar

PTC Therapeutics’ Earnings Call: Strong 2024 Amid Challenges

TIPRANKS
·
01 Mar

PTC Therapeutics Is Maintained at Overweight by JP Morgan

Dow Jones
·
01 Mar

Q4 2024 PTC Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents
·
01 Mar

Stock Track | PTC Therapeutics Soars 5.28% Pre-Market on Strong Earnings, Promising Pipeline Updates and Bullish Analyst Views

Stock Track
·
28 Feb

Stock Track | PTC Therapeutics Plummets 11.43% as JPMorgan Cuts Price Target

Stock Track
·
28 Feb

RBC Capital Adjusts PTC Therapeutics Price Target to $64 From $63, Maintains Outperform Rating

MT Newswires Live
·
28 Feb

PTC Therapeutics: Buy Rating Backed by Promising Clinical Catalysts and Solid Commercial Foundation

TIPRANKS
·
28 Feb